Marshall Edwards has announced the pre-clinical study results of NV-128 in chemotherapy-resistant ovarian cancer stem cells.
The study demonstrated that NV-128 can specifically target the mitochondria in patient-derived ovarian cancer stem cells to induce cell death in chemo-resistant cell population.
Previous studies conducted at Yale University, US, showed that NV-128 is able to inhibit tumour growth in an ovarian cancer animal model without inducing significant toxicity.
It found that once administered, NV-128 is demethylated in vivo to NV-344, its active metabolite, which has been shown to be more potent than NV-128 in pre-clinical research studies.
The company said it plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug application to the US Food and Drug Administration by the first quarter of 2012.